-

Xcell Biosciences to Showcase Future of Cell Manufacturing at ISCT 2024

Company will offer first public demonstration of its AVATAR Foundry technology and enroll new participants in its beta access program

SAN FRANCISCO--(BUSINESS WIRE)--Xcell Biosciences Inc. (Xcellbio), an innovative technology company focused on cell and gene therapy manufacturing applications, today announced its speaker lineup and activities for the upcoming ISCT 2024, the annual meeting of the International Society for Cell & Gene Therapy, taking place May 29 – June 1 in Vancouver, British Columbia. Along with AmplifyBio and the University of Virginia, Xcellbio will offer poster presentations of its AVATAR technology in T cell manufacturing and analytical applications.

“ISCT is the leading organization dedicated to cell and gene therapies, and we look forward to this conference every year to meet with customers, collaborators, and anyone else whose cell therapy development efforts can be accelerated by our unique approach to conditioning cells for more potent and persistent cancer-killing abilities,” said Brian Feth, co-founder and CEO at Xcellbio.

Building upon the success of the AVATAR system previously launched for cell and gene therapy research and development, the cGMP AVATAR Foundry system represents the latest platform advancement to deliver novel capabilities for improving expansion and potency of cell therapies. The AVATAR product family now covers small-scale research and process development capabilities, as well as scale-up bioreactor manufacturing platforms for metabolically reprogramming therapeutic cells to improve their expansion, potency, and persistence in the tumor microenvironment.

Booth Activities

Xcellbio can be found at booth #704 in the ISCT exhibit hall. Conference attendees may visit the booth to see the AVATAR Foundry system and experience a live demonstration of the instrument. In addition, information about participating in the expanded beta access program for the AVATAR Foundry system will be available.

Poster Presentations

The following posters will include data generated with the AVATAR system:

Poster #933: Adapting T cells for the Tumor Microenvironment (TME) During Manufacturing for Improved Anti-Tumor Potency
Presenter: Craig Fett, AmplifyBio

Poster #1009: Acclimation of Effector T Cells to Tumor Microenvironment Induces Enhanced Proliferation and Anti-tumor Activity Against Breast Cancer Cell Lines
Presenter: Archana Thakur, University of Virginia

Poster #912: Modulating Environmental Conditions to Enhance Production of Potent Cell Therapies for the Solid Tumor Microenvironment
Presenter: Yelena Bronevetsky, Hadia Lemar, Evan Massi, Candy Garcia, Xcellbio

More information about the beta access program is available at https://www.xcellbio.com/gmp.

About Xcell Biosciences

Xcellbio is driven by its mission to enhance the performance and safety of cell and gene-based therapies through the design and development of revolutionary technology platforms. The company’s commercial instruments and software allow researchers to discover novel insights into immune and tumor biology and enable the translation of these insights at patient scale through the development of its pioneering cGMP cell therapy manufacturing platform. Based in San Francisco, Xcellbio can also be found online at www.xcellbio.com.

Contacts

For Xcellbio
Suzanne Howard
suzanne@bioscribe.com

Industry:

Xcell Biosciences Inc.

Release Versions
English

Contacts

For Xcellbio
Suzanne Howard
suzanne@bioscribe.com

More News From Xcell Biosciences Inc.

Xcell Biosciences Announces Joint Research Collaboration with Thermo Fisher Scientific to Advance the Next Generation of Cell Therapies

SAN FRANCISCO--(BUSINESS WIRE)--Xcell Biosciences (Xcellbio), a San Francisco-based instrumentation company focused on cell and gene therapy applications, today announced a strategic collaboration with Thermo Fisher Scientific Inc., the world leader in serving science, to advance research in regulatory T cells (Tregs) and tumor-infiltrating lymphocytes (TILs). While significant progress has been made in the cell therapy space leveraging Chimeric Antigen Receptor T (CAR T) cells, this collaborat...

Xcellbio Announces Commercial Licensing & Supply Agreement to Support Commercial Production of Gene Therapy for Sickle Cell disease

SAN FRANCISCO--(BUSINESS WIRE)--Xcellbio announced today that it had granted bluebird bio, Inc., a commercial license and entered into a supply agreement for the use of Xcellbio’s proprietary cell manufacturing technology, AVATAR™, to support commercialization of LYFGENIA® gene therapy for the treatment of sickle cell disease for the treatment of patients 12 years of age or older with sickle cell disease and a history of vaso-occlusive events. Xcellbio’s proprietary technology platform, AVATAR™...

Xcellbio Announces Partnership with Planet Innovation to Develop and Manufacture Next Generation Instruments to Improve potency for Rapid Cell Therapy Manufacturing

MELBOURNE, Australia--(BUSINESS WIRE)--Xcell Biosciences Australia Pty Ltd (Xcellbio), an Australian affiliate of the San Francisco-based instrumentation company focused on cell and gene therapy applications, has announced that it has entered into an agreement with the Royal Perth Hospital to use its AVATAR™ Foundry platform in a clinical trial focused on rapid manufacturing of more potent cancer-killing cell therapies. Planet Innovation, an Australian headquartered medtech innovation company,...
Back to Newsroom